The Role of Extracellular Vesicles and Microparticles in Central Nervous System Disorders: Mechanisms, Biomarkers, and Therapeutic Potential Authors: Soroush Najdaghi, Delaram Narimani Davani, Hamed Fouladseresht, Narges Ebrahimi, Mark J M Sullman, Marjan Moradi, Nahid Eskandari Published: 2024 ABSTRACT AbstractMicroscopic, membranous vesicles known as extracellular vesicles (EVs) have been proposed to play a role in the mechanisms underlying central nervous system (CNS) diseases. EVs are secreted by a variety of cells, including myeloid, endothelial, microglial, oligodendroglial, and mesenchymal stem cells (MSCs). Body fluids such as plasma, urine, and cerebrospinal fluid (CSF) contain microparticles (MPs). The detection of MPs in CSF may indicate genetic or environmental susceptibility to conditions such as schizophrenia, schizoaffective disorder, and bipolar disorder. MPs of different origins can exhibit changes in specific biomarkers at various stages of the disease, aiding in the diagnosis and monitoring of neurological conditions. However, understanding the role and clinical applications of MPs is complicated by challenges such as their isolation and dual roles within the CNS. In this review, we discuss the history, characteristics, and roles of MPs in CNS diseases. We also provide practical insights for future research and highlight the challenges that obscure the therapeutic potential of MPs.Keywords: Alzheimer’s disease, Parkinson's disease, Neuroimmunology, Microparticles, Extracellular vesicles, Central nervous system Introduction Central nervous system (CNS) disorders, including ischemic stroke, Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS), are the second leading cause of mortality worldwide (Feigin et al. 2019; Megur et al. 2020; Eyileten et al. 2021; Organization 2006; Najdaghi et al. 2022). Notably, the significance of CNS diseases as a major public health concern is amplified by the stigma associated with them, and this issue is further exacerbated in aging populations (Béjot and Yaffe 2019; Lotfi et al. 2022). Extracellular vesicles (EVs) are cell-derived particles involved in CNS development and disease, ranging from 30 to 5000 nm in diameter. The three main categories of EVs include exosomes, microvesicles (MVs), and apoptotic bodies (ApoBDs) (Di Maio et al. 2019; Meng et al. 2020). These categories differ in size, contents, specific markers, fusion with lysosomes, density, and shedding mechanisms (Di Maio et al. 2019; Meng et al. 2020). Once considered non-functional, exosomes and MPs are now recognized as effective cell-free treatments for a wide variety of CNS disorders. However, the role of ApoBDs remains incompletely understood; they are anucleated, heterogeneous, membrane-encased vesicles ranging from 0.1 to 1 μm in diameter. MPs are released into circulation through apoptosis or cell activation (Batool et al. 2013). MPs contain nucleic acids, proteins, and lipids, enabling extensive interconnection between CNS and non-CNS cells, primarily due to their small size and ability to cross the blood–brain barrier (BBB) (Saint-Pol et al. 2020; Paolicelli et al. 2019). MPs can mediate neuroinflammation, which has been identified as an underlying mechanism in almost all neurodegenerative illnesses (Bhatia et al. 2021; Guzman-Martinez et al. 2019; Jones et al. 2019; Rizk et al. 2021; Rashidi et al. 2020; Kumar et al. 2017a). Neuroinflammation can exacerbate the progressive deterioration of several CNS disorders, such as stroke and traumatic brain injuries (TBIs). For example, microglia-derived MPs (MDMPs) contribute to lipopolysaccharide (LPS)-induced neuroinflammation in vitro and neuroinflammation following TBI in vivo (Kumar et al. 2017b). Moreover, due to their markedly elevated concentrations in neuroinflammatory conditions, MPs may serve as promising biomarkers for many neurological diseases (Horstman et al. 2017; McGeer and McGeer 2011). In the CNS, various MPs play a significant role in the pathogenesis of neuroinflammation. These include brain-derived MPs (BDMPs) in stroke (Chen et al. 2019; El-Gamal et al. 2019), platelet-derived MPs (PMPs) and endothelial-derived MPs (EMPs) in AD (Hosseinzadeh et al. 2018), and increased MP shedding in cerebrospinal fluid (CSF) in schizophrenia (Mobarrez et al. 2013). Blocking the excretion of specific MPs has been proposed as a strategy to mitigate neuroinflammation-induced CNS damage. For example, treatment with Lactadherin, a phosphatidylserine-binding glycoprotein, has been shown to significantly improve neurological function, reduce lesion size, BBB leakage, axonal or white matter damage, and the expression of inflammatory factors in vivo by inhibiting BDMP-induced neuroinflammation (Chen et al. 2019). Despite originating from a single cell type, MDMPs can exert dual effects on the CNS (Trotta et al. 2018; Song et al. 2020). Additionally, modified EVs may act as carriers for neurodegenerative diseases, such as mutant MPs in Huntington’s disease (HD) (Jeon et al. 2016; Lee and Kim 2017), while EV engineering can enhance neuron-specific targeting in therapeutic approaches (Alkaff et al. 2020). The diverse and complex roles of MPs complicate the understanding of their therapeutic potential and present significant challenges in drug development efforts. In this review, we address the challenges that obscure the use of MP levels as reliable biomarkers and the complexities associated with employing MPs as therapeutics. We explore the molecular processes underlying the formation of MPs and their actions within the CNS. Additionally, we examine the physiological and pathophysiological roles of MPs in the CNS, including their contribution to CNS development. Finally, we outline therapeutic approaches that utilize MPs and provide valuable insights into the field of cell-free therapeutics. Microparticles: History, Characteristics, and Classifications In 1946, the removal of PMPs by high-speed centrifugation was shown to extend the coagulation time of recalcified plasma in normal individuals, as PMPs contain phosphatidylserine (PS), an anionic phospholipid (Chargaff and West 1946). In 1967, Peter Wolf et al. first identified MPs while researching blood coagulation. They observed that MPs were shed following platelet activation and coined the term “platelet dust,” as they did not initially recognize a major role for these particles. Furthermore, it was demonstrated that MPs could support thrombin generation in the absence of platelets (Hargett and Bauer 2013; Wolf 1967). The perception of MPs as merely procoagulant platelet dust has evolved, and recent research has redefined MPs as potent, versatile membrane-bound entities that play a central role in the pathogenesis of a wide range of illnesses (Słomka et al. 2018; Kumar et al. 2020). Moreover, MPs transport functionally important cargoes such as nucleic acids (including DNAs, mRNAs, and small non-coding RNAs (sncRNAs)), proteins, and lipids to distant fusion sites, thereby facilitating complex intercellular communication (Rak 2010; Kahlert and Kalluri 2013). The membranous packaging of MP protects their contents from biodegradation, enhancing their targeting precision (Rak 2010; El-Hefnawy et al. 2004). Characteristics, Origins, and Separation Process of Mps EVs are generally distinguished by their size, density in sucrose, morphology, specific markers, and excretion mechanisms (Akers et al. 2013; Al-Nedawi et al. 2008; Bian et al. 2019a; Minciacchi et al. 2015a; Stahl and Raposo 2018). MPs are characterized by their spherical morphology, a size of 100–1000 nm, and an average density of about 1.15 g/ml (Kastelowitz and Yin 2014). They are typically larger than exosomes (40–100 nm) but smaller than ApoBDs (> 1000 nm) (Théry et al. 2009). Additionally, MPs exhibit greater heterogeneity than exosomes in terms of size and content (Stahl and Raposo 2018). Although the proteomic profile of MPs greatly depends on their isolation method, as a product of their biosynthesis procedure, MPs present marker proteins regardless of their cellular origin (Østergaard et al. 2012). When MPs separate from their original membrane through an outward budding process, they primarily contain proteins related to the cytosol and plasma membrane. These include proteins that cluster at the plasma membrane surface, such as tetraspanins (Kleijmeer et al. 1998; Zöller 2009). These proteins may be present in MPs at concentrations up to 100 times higher than in the cell lysate (Kleijmeer et al. 1998; Zöller 2009). Other proteins commonly identified in MPs include cytoskeletal proteins, heat shock proteins (HSPs), integrins, and proteins that exhibit post-translational modifications, such as glycosylation and phosphorylation (Heijnen et al. 1999; Vizio et al. 2012; Morello et al. 2013). Glycan-binding proteins on the surface of MPs may play a crucial role in how MPs are targeted and interact with other cells (Yáñez-Mó et al. 2015). The biogenesis process of MPs accounts for the presence of cytosolic and plasma membrane proteins. Conversely, proteins specifically associated with various endosomal organelles and the nucleus, which do not contribute to MP biosynthesis, are notably absent in MPs, especially when compared to the cell’s lysate (Sinha et al. 2014; Christianson et al. 2013). The lipid content of MPs closely resembles that of the original plasma membrane (Doyle and Wang 2019); however, the asymmetric lipid distribution of MPs differs from the typical arrangement across the two leaflets of the cell membrane. After MP detachment, aminophospholipids such as phosphatidylserine (PS) and phosphatidylethanolamine (PE) do not remain confined to the internal leaflet of the membrane but instead spread homogenously across the bilayer lipid enclosure (Kastelowitz and Yin 2014; Scott et al. 1984; Hugel et al. 2005). Similar to MPs, ApoBDs generally present PS on their outer membrane. Additionally, several studies have identified exposed PS on the surfaces of MPs and exosomes derived from tumor cells, highlighting their potential as tumor biomarker (Lea et al. 2017; Battistelli and Falcieri 2021). MPs may originate from various cell types, including stem cells (Bruno et al. 2009), blood cells (e.g., platelets) (Zaldivia et al. 2017), and neuronal and glial cells (Grimaldi et al. 2019). They are found in both plasma and CSF. Notably, elevated levels of MPs in plasma and CSF have been associated with CNS illnesses (Hosseinzadeh et al. 2013; Colombo et al. 2012). Separating EVs solely by size or density is not accurate due to the overlap between exosomes and MPs in these characteristics. Specific markers of MPs include Annexin-V, ADP-ribosylation factor 6 (ARF6), CD40, and VCAMP3 (Bian et al. 2019a; Stahl and Raposo 2018). However, several protein markers and histones are present in more than one EV class, further complicating their isolation. For example, specific exosome markers such as CD63 and CD81 may also be found on hematopoietic stem cell (HSC)-derived MPs (Booth et al. 2006). Consequently, exosomes and MPs smaller than 150 nm are collectively recognized as small EVs (EVs) (Brennan et al. 2020; Mastoridis et al. 2018). The lack of highly specific isolation methods is a major hurdle to the detection and application of disease-specific MPs as biomarkers or therapeutic agents (Whiteside 2017; Jeppesen et al. 2019). Flow cytometry (Robert et al. 2012), nanoparticle tracking analysis (NTA) (Dragovic et al. 2011), dynamic light scattering (DLS) (Lawrie et al. 2009), tunable resistive pulse sensing (TRPS) (Momen-Heravi et al. 2012), transmission electron microscopy (TEM) (Van der Pol et al. 2014), atomic force microscopy (AFM) (Liu and Butte 2012; Sharma et al. 2010), immunoblotting (Witwer et al. 2013), enzyme-linked immunosorbent assay (ELISA) (Pol et al. 2013), and proteomics (Choi et al. 2015) are all methods used to identify EVs in MPs. Among these, flow cytometry is the most commonly used method for MP detection and enables the identification of MPs as small as 150 nm (Perfetto et al. 2004). However, flow cytometry of the smallest MPs is limited by swarm detection, a phenomenon where multiple MPs are detected as a single event (Van der Pol et al. 2014). Additionally, the low quantity of antibody binding sites in small MPs can sterically hinder staining (Erdbrügger and Lannigan 2016; Suárez et al. 2017). Consequently, flow cytometry may underestimate the surface expression and quantity of MPs. Table 1 outlines the main characteristics, roles, and detection methods of EV subclasses. Table 1Comparative characteristics of EVs categoriesCharacteristic/EV classMPsExosomesApoBDsFirst discoveredWolf et al. [1967] (Wolf 1967)Harding and Stahl [1983] (Harding and Stahl 1983)Kerr et al. [1965] (Kerr et al. 1972)ShapeRound-shaped vesiclesRound or cup-like vesiclesRound to oval-shaped vesiclesSizea100 nm–1 μm40–150 nm500 nm–5 μmDensity in sucrose1.04–1.07 g/ml1.13–1.19 g/ml1.16–1.28 g/mlMain compositionRNAs (both coding and non-coding), DNAs, membrane lipids, membrane proteinsRNAs (both coding and non-coding), rarely DNAs, proteins, lipids, and origin cell metabolitesSectioned RNA or DNA, intracellular fragments, and cellular organelles (e.g., mitochondria)DistributionHeterogeneousRelatively homogenousHeterogeneousSpecific biomarkersLack of specific markers, Annexin-V, CD63, selectins, integrin, ARF6, metalloproteinase, rich in PS, CD40, and VCAMP3Tetraspanins (CD9, CD63, CD81], Flotillin, Clathrin, Tsg 101, trace levels of PS Alix, ESCRT, and Tsg 101Annexin-V, DNA, Histones, PS, Thrombospondin, C3bIdentification or separation methodsUltracentrifugation, NTA, TEM, DLS, flow cytometry, density-gradient, ciliated nanowire-on-microvillar, acoustic-based, inertial lift force-based, surface-modified, nanoshearingUltracentrifugation, TEM, SEM, AFM, NTA, DLS, resistive pulse sensing, ELISA, flow cytometry, FACS, microfluidics, electrochemical biosensors, density-gradient, ciliated nanowire-on-microvillar, acoustic-based, inertial lift force-based, surface-modified, nanoshearingDifferential centrifugation, flow cytometry, FACSElements involved in biosynthesisESCRT I, III ceramide, tetraspanin, ARF6, cytoskeleton flippaseSyntenin ESCRT 0-II and ESCRT III, Ceramide, Tetraspanins, SyndecanMAPKs (e.g., ERK JNK, and the p38-MAPK)Stages of biosynthesisBudds outwardly, directly from the cell membraneInward budding of the endosomal membrane is followed by MVBs formation, which encloses ILVs. Then, final vesicles are shed after MVBs fusion with membranesOutward membrane budding during cellular fragmentation during apoptosisRole in immunoregulationAntigen presentation, immune activation (e.g., pro-inflammatory effect), immune inhibition, immunosurveillance, and intercellular crosstalkAntigen presentation, immune activation, immune inhibition, immunosurveillance, and intercellular crosstalkMaintenance of immunological silence (e.g., anti-inflammatory effect), infection spreading, and autoimmunityaAlthough slight inconsistencies exist regarding EVs size in the literature, the size overlap of EVs classes remains valid and is present in most studies (Coumans et al. 2014; Gardiner et al. 2013; Ståhl et al. 2019)Table adapted partially from Lee et al. (2017), Bian et al. (2019b); Conde-Vancells et al. (2008), Gurunathan et al. (2019), Atkin-Smith et al. (2017), Ko et al. (2016), Greening et al. (2015), Caruso et al. (1486), Willms et al. (2016)AFM atomic force microscopy, ApoBD apoptotic body, ARF 6 ADP-ribosylation factor 6, CD cluster differentiation, DLS dynamic light scattering, ELISA enzyme-linked immunosorbent assay, ERK extracellular signal-regulated kinase, ESCRT endosomal sorting complexes required for transport, EV extracellular vesicle, FACS fluorescence-activated cell sorting analysis, JNK c-Jun NH2-terminal kinase; ILV intraluminal vesicle, MAPK mitogen-activated protein kinase, MP microparticle, MVB multivesicular body, NTA nanoparticle tracking analysis, PS phosphatidylserine, SEM scanning electron microscope, TEM transmission electron microscope, Tsg 101 tumor susceptibility gene 101 Comparative characteristics of EVs categories aAlthough slight inconsistencies exist regarding EVs size in the literature, the size overlap of EVs classes remains valid and is present in most studies (Coumans et al. 2014; Gardiner et al. 2013; Ståhl et al. 2019) Table adapted partially from Lee et al. (2017), Bian et al. (2019b); Conde-Vancells et al. (2008), Gurunathan et al. (2019), Atkin-Smith et al. (2017), Ko et al. (2016), Greening et al. (2015), Caruso et al. (1486), Willms et al. (2016) AFM atomic force microscopy, ApoBD apoptotic body, ARF 6 ADP-ribosylation factor 6, CD cluster differentiation, DLS dynamic light scattering, ELISA enzyme-linked immunosorbent assay, ERK extracellular signal-regulated kinase, ESCRT endosomal sorting complexes required for transport, EV extracellular vesicle, FACS fluorescence-activated cell sorting analysis, JNK c-Jun NH2-terminal kinase; ILV intraluminal vesicle, MAPK mitogen-activated protein kinase, MP microparticle, MVB multivesicular body, NTA nanoparticle tracking analysis, PS phosphatidylserine, SEM scanning electron microscope, TEM transmission electron microscope, Tsg 101 tumor susceptibility gene 101 Mechanisms Underlying MP Shedding and Reuptake The formation of exosomes involves endocytosis (Bökel and Brand 2014). This process is followed by the fusion of endocytic vesicles with early endosomes, leading to the formation of multivesicular bodies (MVBs). MVBs then encircle smaller membranous entities known as intraluminal vesicles (ILVs). When the enclosing MVB fuses with the plasma membrane, ILVs are released as exosomes (Cocucci and Meldolesi 2015). In contrast, MPs bud outwardly from the cell membrane and are released into the extracellular space by exocytosis (Doormaal et al. 2009; Muralidharan-Chari et al. 2010). Interestingly, MPs may form during apoptosis, similar to ApoBDs. However, MPs are pinched off in early apoptosis, whereas ApoBDs are shed later in the process (Kakarla et al. 2020). The lipid composition and arrangement of the peripheral cytoskeleton influence the fluidity and bendability of the membrane, significantly affecting the release of MPs (Janmey and Lindberg 2004; Blanchard and Busik 2017). Additionally, cholesterol depletion reduces MP shedding (Conde et al. 2005). MPs exhibit distinctive lipid configurations, for instance, they primarily show an increase in sphingomyelin and externalization of PS, a lipid typically confined to the inner leaflet of the bilayer membrane (Conde et al. 2005; Haraszti et al. 2016). Enzymes involved in lipid transport between the leaflets of the plasma membrane, such as calpain, scramblases, flippases, and floppases, may also play a role in MP biogenesis (Al-Nedawi et al. 2008; Hugel et al. 2005; Minciacchi et al. 2015b; Clark 2011; Piccin et al. 2007). Acidic sphingomyelinases convert sphingomyelin to ceramide, playing a key role in MP formation. Neutral sphingomyelinases perform a similar function during exosome biosynthesis (Menck et al. 2017). Ceramide, a cone-like lipid produced by sphingomyelinase, induces curvature in the membrane and accelerates MP pinch-off (Menck et al. 2017; Guo et al. 2015; Hoehn et al. 2017; Awojoodu et al. 2014; Bianco et al. 2009; Shamseddine et al. 2015). Several crucial elements involved in MPs release are found in the cytoskeleton. These cytoskeletal components include actins, microtubules, movement molecules (e.g., kinesin, myosin), fusion machinery (e.g., soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs), and tethering elements) (Cai et al. 2007). The Ras homolog family member A (RhoA) modulates actin arrangement and cytoskeletal contractility. RhoA enhances MP release by influencing extracellular signal-regulated kinase (ERK) and Rho-associated protein kinase (ROCK). Additionally, substances involved in MP formation include ARF6, endosomal sorting complexes required for transport (ESCRT) I and III, tetraspanins, and syndecan (Akers et al. 2013; Bian et al. 2019a). The ESCRTs facilitate the maturation of enclosed vacuoles, enabling them to carry ubiquitinated cargo to early endosomes (Denzer et al. 2000). Several of the elements phosphorylate the myosin light chain at the neck of MPs, enhancing myosin contractility and supporting the division and release of the produced MPs (D'Souza-Schorey and Chavrier 2006; Muralidharan-Chari et al. 2009; Schlienger et al. 2014; Niel et al. 2018). Recent research suggests that some ESCRTs are involved in the formation of both exosomes and MPs, indicating that these EVs are shed via distinct yet overlapping processes (Wang and Lu 2017; Dreyer and Baur 2016; Nabhan et al. 2012; Sedgwick and D'Souza-Schorey 2018; Maas et al. 2017). After release, EVs circulate in the extracellular fluid near their excretion site, where they either deteriorate or are reabsorbed by other cells. Alternatively, EVs may travel long distances via diffusion and be deposited in body fluids such as CSF, blood, and urine (Cocucci et al. 2009). The reuptake of MPs is influenced by their size. For instance, there is an inverse relationship between the size of MPs and IgM-modulated MP reabsorption by macrophages, suggesting that IgM may facilitate the clearance of smaller MPs (Caponnetto et al. 2017). The formation of MPs and their effects on physiological nervous system functions are illustrated in Fig. 1. Formation and roles of EVs in physiological CNS function. The formation of EV classes and the physiological actions of MPs in brain function and development are demonstrated. Numerous membrane complexes are involved in these mechanisms. Tetraspanin-enriched microdomains (TEM) are omnipresent membrane elements synthesized via tetraspanins linked to lipids and comprise integrins, Ig SF receptors, and metalloproteinases. The role of TEMs in EV processing is shown (gray). EVs disseminate by circulation, affecting both the PNS and CNS upon passing through the BBB. MiRs maturation (purple): (i) Pri-miR is transcribed from its corresponding gene in the nucleus. (ii) Pri-miRs are cleaved into pre-miRs, which are exported to the cytosolic space. (iii) Further processing by Dicer and RISC complex results in the production of mature miR. (iv) Mature miRs enter the early endosome. EVs formation MPs (pink): (i) Cargoes aggregate and cellular membrane buds outwardly. (ii) MPs are then detached into the extracellular space. Exosomes (white): (i) Endocytic vesicles cargoes are emptied into early endosomes. (ii) Golgi apparatus exports packages toward the endosome. (iii) Inward budding of the early endosome membrane produces ILVs, and the endosome moves into the late-stage (MVBs). (iv) MVBs may fuse with lysosomes, producing endolysosomes, and leading to degradation of contents. (v) MVBs can fuse with the cellular membrane, leading to the release of ILVs as mature exosomes. ApoBDs, ApoMPs (yellow): (i) Apoptotic stimuli lead to mitochondrial swelling. (ii) Cyt C release leads to caspase-9 activation, followed by Apaf oligomerization and generation of apoptosome. (iii) During early and late apoptosis, ApoBDs and ApoMPs are formed, respectively, with the latter through an unknown pathway. Abbreviations: Alix: alg-2 interacting protein x, Apaf: Apoptotic protease activating factor 1, ApoBD: apoptotic body, ApoMP: Apoptotic microparticle, ARF6: ADP-ribosylation factor 6, CNS: central nervous system, cyt: cytochrome, EGFR: epidermal growth factor receptor, EPSC: Excitatory postsynaptic current, Exo: exosome, FAK: focal adhesion kinase, FLT: FMS-like tyrosine kinase, HGF: hepatocyte growth factor, ICAM: Intercellular adhesion molecule-1, Ig SF: immunoglobulin superfamily, ILV: intraluminal vesicle, MHC: major histocompatibility complex, miR: microRNA, MVB: multivesicular body, MΦ: macrophage, pre-miR: precursor microRNA, Pri-miR: primordial microRNA, RhoA: Ras homolog family member A, RISC: RNA-induced silencing complex, RP: Release probability, RRP: Release-ready pool, TEM: tetraspanin-enriched microdomain, TGF: tumor growth factor, Tsg101: tumor suspectibility gene 101, VEGF: vascular endothelial growth factor. *Notes: Protein structural data retrieved from RCSB PDB (Berman et al. 2000). Created with BioRender.com (BioRender.com Cw. 2020). References: (Akers et al. 2013; Bauer et al. 2011; Brites and Fernandes 2015; Colombo et al. 2012; Hewett et al. 2012; Koniusz et al. 2016; Li et al. 2020; Liu et al. 2014; Soengas et al. 1999; Thompson et al. 2016) Participation of MPs in the Normal CNS Connection MPs play a crucial role in CNS embryonic development. For instance, MPs that are positive for Sonic Hedgehog (Shh), an embryonic morphogen, contribute to early CNS formation (Martí and Bovolenta 2002). Recent research has shown that although Shh-positive MPs (MPsShh+) dampen endothelial cell proliferation and migration, they can promote vessel formation by enhancing endothelial cell adhesion and producing factors that facilitate angiogenesis. Inhibition of the Shh pathway affects the expression of proteins involved in cell adhesion (e.g., RhoA) and vasculogenic elements (Soleti and Martínez 2009; Nagase et al. 2005). While recombinant Shh has been shown to modulate vascular growth in ischemic settings, the angiogenic impact of endogenous Shh remains to be fully elucidated (Martí and Bovolenta 2002). Exposure to oxycodone during pregnancy has been linked to EVs, which is particularly concerning given the widespread abuse of this drug. An in vivo study investigated the effects of in utero oxycodone (IUO) and post-natal oxycodone (PNO) on CNS development. Using RNA-Seq analysis, researchers identified distinct microRNAs (miRs) signatures in brain-derived EVs (BDEVs) associated with IUO and PNO exposure. These miRNAs regulated key functional pathways related to brain development, which were disrupted in IUO offspring. Recently, extended exposure of primary 14-day in vitro neurons to IUO decreased spine density compared to exposure to BDEVs from PNO and saline groups. miR-504 directly targets Dopamine Receptor D1 (DRD1] and indirectly influences DRD2 production (Huang and Li 2009; Zhang et al. 2013; Guan et al. 2015). Furthermore, research showed that elevated levels of miR-504 in BDEVs from the IUO subjects correlated with higher expression of DRD1 and DRD2 receptors in synapses, a process possibly responsible for the decline in dendritic spines. This is crucial due to the significant role of synaptic connectivity in brain development (Shahjin et al. 2019). Increased levels of neural stem cell (NSC)-derived MPs containing the stem cell marker prominin-1CD133+ can be measured during neurogenesis in developing mouse brains (Marzesco et al. 2005; Marzesco 2013). Although the precise association between the secreted MPs and neuronal differentiation remains undetermined, two hypotheses outline the physiological actions of these MPs. Prominin-1 has been shown to interact with membrane cholesterol and lipid rafts (Thamm et al. 2016). Since lipid rafts play an important role in signal transduction, stem cell-derived MPs may contain elements crucial for cellular differentiation. The other theory suggests that MPCD133+ could be involved in intercellular crosstalk (Marzesco 2013). In the maturing rodent cerebrum, during the early stages of neurogenesis, MPs deposited in the ventricles of the neural tube, including surprisingly small (50–80 nm) and large (600 nm) vesicles that express prominin-1, reach their highest levels (Marzesco et al. 2005). These MPs or exosomes might play a role in the transport of mRNAs that encode pluripotent transcription factors (TFs), enabling the reconfiguration of phenotypes in other cells (Ratajczak et al. 2006). Synaptic Activity EVs have been known to regulate synaptic activity, with initial research recognizing the role of exosomes. AMPARs, which stand for α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors, are the primary excitatory synaptic receptors in the brain and spinal cord. Synaptic function mediates AMPA receptor trafficking through various recycling mechanisms involving endosomes (Zheng et al. 2015). Early studies demonstrated that, following depolarization, undifferentiated nerve cells of the cerebral cortex secreted exosomes containing L1, a neuronal cell adhesion protein, and the GLUR2/3 subunit of AMPA receptors (Fauré et al. 2006; Antonucci et al. 2012). MPs primarily exert their function on the presynaptic area of the excitatory synapse by increasing the readily releasable pool (RRP) of synaptic vesicles and enhancing the probability of release at hippocampal synapses. This process is demonstrated by elevated sucrose-induced exocytosis and a decrease in the paired-pulse ratio in synaptically connected neurons. MPs influence neurotransmission by activating sphingolipid metabolism in nerve cells. Evaluating the metabolism of sphingolipids revealed an increase in ceramide and sphingosine synthesis from sphingomyelin in cultured nerve cells exposed to MPs (Turola et al. 2021). Additionally, pharmacological and genetic suppression of sphingosine production significantly reduced the activating function of MPs. Furthermore, the use of MVs emptied of their luminal components suggested that the presynaptic influence of MPs relies primarily on their surface elements (Bianco et al. 2009; Norman et al. 2010). Consistent with early studies that described the phospholipids of the MP membrane as functional pro-inflammatory components (Thomas and Salter 2010), recent research has shown that the lipid part of MPs pinched off from microglia plays a crucial role in enhancing excitatory neurotransmission. These particles harbor a lipid bilayer that carries anandamide (AEA), an active endocannabinoid, on their surface. This lipid component is essential in modulating neurotransmission. Endocannabinoids (eCBs), bioactive lipids that predominantly regulate synaptic communication in the nervous system, are synthesized by neurons and, notably, by microglia, particularly under inflammatory conditions. The orchestrated interplay between microvesicular lipid layers and anandamide contributes to the intricate modulation of neurotransmission by engaging CB1 receptors on target GABAergic neurons, ultimately resulting in a discernible decrease in inhibitory neurotransmission (Soreq 2014). Further research is warranted to elucidate the active lipids of MPs and to fully identify the receptors responsible for MP recognition and coupling with sphingolipid metabolism in neurons (Turola et al. 2021). The overall role of MDMPs in inducing the release of synaptic vesicles remains unclear. Earlier research suggests that adenosine triphosphate (ATP) release, an activator of MP release, can act as a danger signal. These actions occur when microglia are activated rather than in a resting state (Bianco et al. 2009; Qu et al. 2009; Sarkar et al. 2009). Pro-inflammatory microglia release MPs that could amplify synaptic activity through excessive metabolism of sphingomyelin (Felice et al. 2007; Busche et al. 2008; Centonze et al. 2009). Evidence suggests that the uncontrolled release of MDMPs can result in neurotoxicity. However, recent findings indicate that these MPs play a role in recovery from various CNS diseases by supplying neurons with nutritional resources (Caruso Bavisotto et al. 2019), removing injured cells (Olah et al. 2012), mediate neurogenesis (Butovsky et al. 2006), regulating synapse formation (Roumier et al. 2004), and maintaining synaptic activity (Wake et al. 2009). In response to increased synaptic activity, neurons in the corresponding synapse produce a turn-off signal that affects microglia. Diminished turn-off signals in injured nerve cells cause an imbalance between triggering signals produced by MPs and neuronal inhibitory signals, favoring a reactive microglial state (Mott et al. 2004; Biber et al. 2007; Berman et al. 2000; Neumann et al. 1998). Further research is needed to elucidate the complex roles of microglia in CNS connectivity. Nerve Injury and Regeneration MPs and exosomes play a protective role in the nervous system. For instance, oligodendrocyte-derived exosomes contain myelin and stress-protective elements, offering trophic support to neurons (Krämer-Albers et al. 2007). EVs derived from glial cells enhance neurite development and nerve cell longevity through the interaction between synapsin I and oligomannosidic glycans during depolarization and toxic damage to nerve cells. Although synapsin I is primarily recognized as a nerve cell-specific protein associated with synaptic vesicles, it is synthesized in smaller quantities by astrocytes and is secreted from them within EVs following cellular stress (Wang et al. 2011). Brain damage results in the aggregation of toxic components in nerve cells, whose longevity is enhanced by the production of NEDD4 family-interacting protein 1 (Ndfip1), a protein that interacts with NEDD4 ubiquitin ligases that mediate protein degradation (Napier et al. 2012; Gosselin et al. 2013; Sang et al. 2006). The proteins Ndfip1 and NEDD4 are present in EVs released from neurons and may rapidly remove toxic proteins following damage (Putz et al. 2008). Additionally, Schwann cells surrounding a degenerating or damaged peripheral nerve transport vesicles encircled with two polyribosome-containing membranes into the axon, where their contents are deposited (Hendriks et al. 2008; Twiss and Fainzilber 2009). The role of MPs in physiological processes is summarized in Table 2. Table 2The role of MPs in the physiological function of the nervous systemPhysiological actionMPs origin/typeMain actionStudy modelSpecific role or pathways/genes involvedReferencesDevelopmentT-cell (MPShh+)aActivates vessel formation, and prevents proliferation and migration,In vivo (hind-limb ischemic aged mice)/ in vitro (CEM line T-cells)Mainly acts through the Shh pathwayDecreases anti-angiogenic factors: ↓TGF-β2,Increases pro-angiogenic factors: ↑VEGF, ↑FLT1, ↑HGF, ↑IL-1βImproves EC adhesion: ↑ICAM-1, ↑RhoA, ↑FAKSoleti et al. (Soleti and Martínez 2009; Soleti et al. 2009), Martínez et al. (2006), Kanda et al. (2003), Pola et al. (2001)P14 BDEVmiR−504+bReduces spine densityIn vivo (Sprague–Dawley IUO rats)/ in vitro↑DRD1, ↑DRD2, ↑miR–6318, ↑miR-1188, ↑miR-1306-5p, and ↑miR-128–1-5p, ↓MAP2, ↓DrebrinShahjin et al. (2019)Neural tube fluid NSC MPCD133+Neurogenesis, loss of microvilli, and presentation of pleiomorphicprotuberancesIn vivo (embryonic mice)/ in vitroPossibly involved in pluripotent TFs mRNA carriage, and reacts with cholesterol and lipid rafts,Marzesco et al. (2005), Thamm et al. (2016)Synaptic activityMDMPSynaptic activity inductionIn vivo (A-SMase KO mice)/ in vitro↑mEPSC frequency, ↑release probability, ↑sphingolipid metabolism, ↑sphingosine and ceramide formation, and ↑RRP of vesiclesDoes not alter mEPSC amplitudeAntonucci et al. (2012)MDMPSpine synapse plasticityIn vivo (helplessness MDD rats, Sprague–Dawley SNL rats)/in vitro (N9 cells)Chiefly acts via the P2X7-p38 pathway,IL-1β → PWL and PWT,↑sEPSC frequency, ↑sEPSC amplitudeLi et al. (2017a), Otrokocsi et al. (2017)Brain MPsSynaptogenesisIn vivo (embryonic and newborn rats)/ in vitroRough MPs ⇔ membrane differentiationFrumkinda et al. (1991)Nerve injury and regenerationAnti-inflammatory ADMSC-derived MPsNerve regeneration enhancementIn vivo (rat sciatic nerve transection model)/ in vitroImproves assessments of walking track, electrophysiologic, muscle mass, histomorphometric, and immunohistochemicalRaisi et al. (2014)GMSC EVSchwann cell-based nerve repairIn vivo (Female C57BL/6 J mice/Sprague–Dawley rats)/in vitro (RT4-D6P2T Schwann cell line)Accelerates Schwann cell proliferation and migration, ↑c-JUN, ↑Notch1, ↑GFAP, and ↑SOX2Mao et al. (2019)aSome rows indicate the role of Shh summarized for several studies. Therefore, results may be attributed to the specific mentioned EV, rather than a single studybThe + sign indicates being chiefly enriched in a particular componentADMSC adipose-derived mesenchymal stem cell, BDEV brain-derived extra cellular vesicle, CD cluster differentiation, DRD Dopamine Receptor D, EC endothelial cell, eEPSC: excitatory postsynaptic potential, EV extracellular vesicle, FAK focal adhesion kinase, FLT1 vascular endothelial growth factor receptor, GFAP glial fibrillary acidic protein, GMSC gingival mesenchymal stem cell, HGF hepatocyte growth factor, ICAM intercellular adhesion molecules, IL interleukin, IUO in utero oxycodone, KO knockout, MAP2 microtubule-associated protein 2, MDD major depressive disorder, MDMP microglia-derived microparticle, mEPSC miniature excitatory postsynaptic current, miR microRNA, MP microparticle, PWL paw withdrawal latency, PWT paw withdrawal threshold, RhoA Ras homolog family member A, RRP release-ready pool, SNL spinal nerve ligation, Shh sonic hedgehog, SOX2 SRY (sex determining region Y)-box 2, TF transcription factor, TGF transforming growth factor, VEGF vascular endothelial growth factor The role of MPs in the physiological function of the nervous system Mainly acts through the Shh pathway Decreases anti-angiogenic factors: ↓TGF-β2, Increases pro-angiogenic factors: ↑VEGF, ↑FLT1, ↑HGF, ↑IL-1β Improves EC adhesion: ↑ICAM-1, ↑RhoA, ↑FAK Neurogenesis, loss of microvilli, and presentation of pleiomorphic protuberances ↑mEPSC frequency, ↑release probability, ↑sphingolipid metabolism, ↑sphingosine and ceramide formation, and ↑RRP of vesicles Does not alter mEPSC amplitude Chiefly acts via the P2X7-p38 pathway, IL-1β → PWL and PWT, ↑sEPSC frequency, ↑sEPSC amplitude aSome rows indicate the role of Shh summarized for several studies. Therefore, results may be attributed to the specific mentioned EV, rather than a single study bThe + sign indicates being chiefly enriched in a particular component ADMSC adipose-derived mesenchymal stem cell, BDEV brain-derived extra cellular vesicle, CD cluster differentiation, DRD Dopamine Receptor D, EC endothelial cell, eEPSC: excitatory postsynaptic potential, EV extracellular vesicle, FAK focal adhesion kinase, FLT1 vascular endothelial growth factor receptor, GFAP glial fibrillary acidic protein, GMSC gingival mesenchymal stem cell, HGF hepatocyte growth factor, ICAM intercellular adhesion molecules, IL interleukin, IUO in utero oxycodone, KO knockout, MAP2 microtubule-associated protein 2, MDD major depressive disorder, MDMP microglia-derived microparticle, mEPSC miniature excitatory postsynaptic current, miR microRNA, MP microparticle, PWL paw withdrawal latency, PWT paw withdrawal threshold, RhoA Ras homolog family member A, RRP release-ready pool, SNL spinal nerve ligation, Shh sonic hedgehog, SOX2 SRY (sex determining region Y)-box 2, TF transcription factor, TGF transforming growth factor, VEGF vascular endothelial growth factor MPs in Neurological Diseases Multiple Sclerosis Relapsing–remitting MS (RRMS) is the most common type of MS, affecting 85% of cases. RRMS typically presents its first symptoms in the early 20 s and is characterized by sporadic attacks, with remission periods lasting from weeks to years (Lucchetta et al. 2020; Dutta and Trapp 2014; Nabizadeh et al. 2023). Several drugs have been proposed for the treatment of RRMS. IFN-β has been a first-line therapy for over a decade (Limmroth et al. 2011). Evidence from trials suggests that Natalizumab is a highly effective monotherapy for severe cases. Natalizumab is a humanized monoclonal antibody that binds to α4β1-integrin (VLA-4), a molecule that facilitates leukocyte movement and acts as a pro-inflammatory element (Hutchinson 2007). Recent studies have investigated the effects of various treatments on MS at the level of MPs. One study found a significant reduction in EMPsCD31+ from 6 to 12.5 months after treatment with IFN-β, suggesting that EMPs may serve as a biomarker for therapy response in MS (Sheremata et al. 2006a). Another study found that IFN-β and teriflunomide significantly reduced the secretion of MOMPs. Although a significant reduction in MP levels was observed in response to Fingolimod, IFN-β, and teriflunomide, compared to both untreated and MS patients, this effect was not significantly different between treatments. However, teriflunomide treatment began to prominently affect MP levels 2 months after initiation, by downregulating the expression of the purinergic P2X7 receptor and inflammasome components, while IFN-β showed its first effects after 6 months. It is important to note that Fingolimod, a second-line treatment for MS, is typically prescribed to patients who have not responded adequately to first-line therapies. This, combined with the absence of prior first-line treatment for Fingolimod recipients, may influence these outcomes (Blonda et al. 2017a). Types of Cellular Particles Involved in MS Platelet-Derived MPsCD61+ In MS patients, an increased risk of cardiovascular dysfunction, particularly prothrombic events, has been attributed to flawed platelet performance. Flow cytometry evaluations have shown elevated levels of platelet activation markers in the blood of MS patients. A recent study aimed to investigate the extent of platelet activation in individuals with chronic stage MS (secondary progressive MS, SPMS) and their response to normal platelet activators. Platelet activation and responsiveness were evaluated via flow cytometry by measuring P-selectin production (CD62P), activation of the GP IIb/IIIa complex (procaspase activating compound (PAC)-1 binding elements), and biosynthesis of platelet MPs (PMPs) alongside platelet masses in agonist-induced and non-induced whole blood specimens. The results indicated that platelets are chronically activated in SPMS and exhibit hyperreactivity to natural inducers such as ADP and collagen (Blonda et al. 2017b; Morel et al. 2017; Roshanisefat et al. 2014; Alvarez et al. 2011; Minagar and Alexander 2003). All types of MS exhibit elevated levels of PMPs and EMPs, whereas CIS does not. This suggests that platelet malfunction may occur following endothelial dysfunction as the illness progresses. Platelets have been found in MS lesions in humans and the CNS of rodents in the Experimental Autoimmune Encephalomyelitis (EAE) model, a valuable tool for studying diseases that damage myelin (Robinson et al. 2014; Marcos-Ramiro et al. 2014). Recently, transendothelial electric resistance (TEER) has been used as a measure of BBB disruption, which negatively correlates with endothelial permeability. Using TEER, scientists demonstrated that PMPs from CIS patients do not affect monolayer endothelial permeability, whereas high concentrations of MPs derived from RRMS patients can disrupt the BBB within 4 h (Robinson et al. 2014; Marcos-Ramiro et al. 2014; Fernández-Martín et al. 2012; Bradley 2008). In the EAE model, the illness improves when subjects are depleted of their platelets. This improvement has been linked to a decrease in CNS infiltration of leukocytes. Similar outcomes were observed upon treatment with an anti-CD42b antibody. Notably, CD42b is expressed on the surface of PMPs, suggesting that these vesicles may play a role in disease progression and warrant further investigation (Marcos-Ramiro et al. 2014). In addition, PMPs present P-selectin on their surface and attach to P-selectin glycoprotein ligand-1 (PSGL-1] as well as platelet endothelial cell adhesion molecule-1 (PECAM-1 or CD31] from lymphocytes, by increasing the expression of integrins such as α4β1 (VLA-4] (Sáenz-Cuesta et al. 2014). This enhances the attachment of lymphocytes to the endothelial cells and facilitates their transfer into the CNS (Sheremata et al. 2008). Researchers have found that PMPs and EMPs from MS patients increase the permeability of endothelial layers in vitro, indicating their contribution to the disintegration of the BBB (Marcos-Ramiro et al. 2014). An extended T-helper (Th) cell subset in MS cases can be identified by the production of granulocyte–macrophage colony-stimulating factor (GM-CSF) and the C-X-C chemokine receptor type 4 (CXCR4]. Furthermore, the chemokine receptor CXCR4 can be transferred by PMP from cell to cell, indicating its role in MS (Rozmyslowicz et al. 2003). The expression of α4β1 integrin (VLA-4] is a marker of MS and increases endothelial permeability (Mohagheghpour et al. 1992). Leukocytes accumulate in the CNS of RRMS cases (Galli et al. 2019). The BBB plays a major role in the pathophysiology of MS. In the EAE model, antibodies that target VLA-4, but not those that target other adhesion receptors, helped prevent white blood cells from accumulating in the CNS and halted disease progression (Yednock et al. 1992; Palmer 2013). Finally, the secretion of Vascular Endothelial Growth Factor (VEGF) and the synthesis of several other pro-angiogenic elements led to the recognition of angiogenesis in demyelinating MS lesions (Girolamo et al. 2014; Brill et al. 2005). The vasculogenic influence of PMPs was demonstrated in a rat aortic ring in vivo model. PMPs exerted their effects via PI3-kinase, Src kinase, and ERK, while protein kinase C and p38 did not contribute to these outcomes. These effects could be mitigated by suppressing VEGF, basic fibroblastic growth factor (bFGF), and platelet-derived growth factor (PDGF), but not heparanase (Brill et al. 2005). Leukocyte-Derived MPsCD19+ Dysregulation of both B-cell and T-cell MPs is observed in MS. Plasma concentrations of B-cell (CD19 +) MPs were significantly lower in MS cases compared to normal subjects. Notably, treatment with Fingolimod reinstates the levels of B-cell MPs (Zinger et al. 2016). T-cells, both directly and via their secreted MPs, induce monocytes or macrophages, resulting in a significant increase in pro-inflammatory cytokines such as IL‐1β and tumor necrosis factor (TNF), as well as the induction of anti-inflammatory components such as the secreted variant of the IL‐1 receptor antagonist (sIL‐1Ra). This indicates that T-cell-derived MPs (TMPs) may mimic direct T-cell contact due to their monocyte-activating content similar to that of their origin. The blockade of TNF and IL‐1β, unlike sIL‐1Ra, can protect against BBB disintegration in MS (Fellows et al. 2015), even in non-septic conditions (Scanu et al. 2008). These immunoregulatory alterations in TNF and IL‐1β affect monocyte differentiation and the regulatory activity of CD4 + cells (Borsellino et al. 2007; Carpintero et al. 2010; Schenk et al. 2014; Valencia et al. 2006; Vargas et al. 2017; Viglietta et al. 2004; Volpe et al. 2016). Additionally, nitric oxide (NO) is another inflammatory mediator associated with the severity of MS (Giovannoni et al. 1998). Apoptosis mediates the homeostasis of Treg cells as well as Treg cell-mediated suppression (Roshanisefat et al. 2014; Yolcu et al. 2008). TMPs carrying Fas ligand (FasL) on their surface interact with smooth muscle cells through the Fas-FasL apoptosis pathway, activating nuclear factor kappa B (NF-κB) and upregulating NO synthase and cyclooxygenase-2 (COX2] expression (Tesse et al. 2005). TMPs carrying sonic hedgehog (Shh) promote angiogenesis and induce NO production (AgouTii et al. 2007; Martínez et al. 2006). Mast cells can be activated via TMPs through the mitogen-activated protein kinase (MAPK) signaling pathway (Shefler et al. 2010). Mast cells play a crucial role in MS by mediating inflammation and demyelinization, presenting myelin antigens to T-cells, disrupting the BBB, and permitting the entry of inflammatory cells and cytokines. Additionally, the release of histamine by mast cells increases endothelial NO (Tanimoto et al. 2007). Monocyte-Derived MPsCD14+ In non-simulated monocytes, MS cases exhibit higher levels of MPs than healthy individuals (Young et al. 2007). However, upon stimulation with BzATP, only the monocytes from healthy donors exhibited a significant increase in fluorescence. In this study, spectrophotometry was used to evaluate the difference between MOMPs collected from untreated RRMS patients and healthy subjects, as well as to assess the influence of various therapies. Groups of IFN-β- and teriflunomide-treated MS patients were evaluated both before and after treatment. The results suggested that monocytes from MS cases secreted larger quantities of MPs and that all treatments reduced MP secretion. However, only teriflunomide was associated with decreased inflammasome production, which is a key component of inflammation in various diseases (Blonda et al. 2017b; Andrejew et al. 2020). Endothelial-Derived MPs To assess the influence of inflammatory cytokines on the levels of brain-derived EMP secretion and as a simulation of neurovascular inflammation, human cerebral microvascular endothelial cells (BBB hCMEC/D3 cell line) were treated with a control medium or a medium enriched with TNFα, IFN-γ, or a combination of TNFα and IFN-γ. Following this, apical-released MPs (ARMPs) and basolateral-released MPs (BMPs) were assessed using flow cytometry. TNFα, IFN-γ, and TNFα/IFN-γ treatments each significantly increased the numbers of EMPsAnnexin−V+ secreted from brain endothelial cells compared to controls, confirming that cerebrovascular inflammatory stress amplified the release of ARMPs and BMPs in the cerebral endothelium. Additionally, cytokine treatment with TNFα/IFN-γ reduced the size of BMPs but not ARMPs (Wheway et al. 2014; Yun et al. 2019). Several platelet endothelial cell adhesion molecules (PECAMs) are recognized as MP biomarkers in MS, including CD51/CD61 (αV/β3-integrin), PECAM-1 (CD31], and ICAM-1 (CD54] (Lowery-Nordberg et al. 2011). CD31 is an immunoglobulin-superfamily ECAM that is continuously expressed on the apical and junctional endothelial surfaces, as well as on platelets, myeloid cells, and lymphocytes. MPsCD31+ are formed during MS exacerbations, as indicated by clinical presentation and the presence of contrast-enhancing lesions in brain MRIs (Jimenez et al. 2005; Minagar et al. 2001). Additionally, these MPs are associated with early BBB disruption and axonal damage, primarily abating during remission and therapy (Lowery-Nordberg et al. 2011). Another MP marker, CD51 (integrin αV), forms several complexes that bind fibronectin and vitronectin, regulating vascular structure and integrity (Bader et al. 1998). Coupled with CD61, CD51 forms integrin αV/β3, which is expressed by endothelial cells, platelets, macrophages, and neutrophils. MPsCD51+/61+ are elevated at the onset of MS (Minagar et al. 2001), but they do not diminish during remission or treatment (Lowery-Nordberg et al. 2011). MP profiling identified CD51+/61+ as a vascular biomarker for underlying MS disease. Moreover, brain endothelial cells constantly express CD54 (ICAM-1], an MP biomarker, by binding to lymphocyte function-associated antigen-1 (LFA)-1 and membrane complex (Mac)-1. CD54 is upregulated by Th-1 cytokines and can thereby affect BBB properties and vasomotion (Achen et al. 1995). Therefore, the secretion of CD54+ MPs can be used as a blood biomarker of endothelial activation. EMPs, in particular EMPsCD54+, can interact with monocytes to form leukocyte/EMP complexes. EMPs attach to monocytes, inducing the expression of tissue factors. When monocyte/EMP conjugates are formed, monocytes are activated, leading to enhanced transendothelial migration of monocytes and increased inflammation (Blonda et al. 2017b; Jy et al. 2004; Sabatier et al. 2002). Adaptive cellular immunity is activated by antigen-presenting cells (APCs) such as dendritic cells (DCs). After antigen exposure, APCs send signal 1 (peptide-major histocompatibility complex (MHC)), signal 2 (co-stimulatory components), and signal 3 (instructive chemokines) to naive T-cells. Similar to their origin cells, EMPs express components crucial for antigen presentation and T-cell co-stimulation, including β2-microglobulin, MHC-II, CD40, and inducible costimulator ligand (ICOSL/CD275] (Wheway et al. 2014). In MS, APCs promote a self-destructive environment through the release of pro-inflammatory factors and the presentation of myelin epitopes to autoimmune T lymphocytes (Chastain et al. 2011; Greter et al. 2005; McMahon et al. 2005; Spanier et al. 2020). Oligodendrocyte-Derived MPs Several extracellular factors mediate Myelin production. In the developing CNS, oligodendrocyte progenitor cells differentiate into mature oligodendrocytes that begin to encircle axons with myelin sheaths upon receiving signals from the axon or its microenvironment. Scolding et al. were the first to confirm the presence of oligodendroglial MPs in the CSF of MS patients (Scolding et al. 1989). In addition, recent studies have shown that exosome-like vesicles derived from oligodendrocytes inhibit the differentiation of oligodendrocytes and myelin production. Notably, these particles were reduced after treatment with a conditioned nerve cell medium. The inhibitory effect of exosome-like vesicles was prevented by actomyosin contractility blockers (Bakhti et al. 2011; Casella et al. 2020; Gholamzad et al. 2017; Osorio-Querejeta et al. 2018). Impact of Critical Hypertension on Endothelial- and Platelet-Derived Microparticles Elevated EMP excretion is correlated with endothelial damage in MS patients (Combes et al. 1999; Larkin 2001; Sheremata et al. 2006b). The cellular and molecular processes that ultimately result in vascular damage following a significant rise in blood pressure are still unknown. Nonetheless, elevated quantities of EMPs and PMPs, which indicate the activation of endothelium and platelets, could play a prominent role in target organ damage. A recent study demonstrated that both EMPs and PMPs are significantly associated with blood pressure. Furthermore, these associations remained valid even after accounting for various risk factors. These findings suggest that MP concentration may serve as a valuable specific surrogate marker for pressure-triggered platelet or monocyte activation. Finally, due to the combined impact of EMPs and PMPs on coagulation, leukocytes, and endothelium, they likely exacerbate target organ damage in severe hypertension, which is frequently observed in MS and affects the integrity of white and gray matter (Preston et al. 2003; Dossi et al. 2018). Alzheimer’s Disease (AD) Platelets and Amyloid-β The cerebrum affected by AD is characterized by extracellular senile plaques composed of amyloid and intracellular neurofibrillary tangles. Since amyloid-β (Aβ) peptides were identified as the major component in amyloid cerebrovascular senile plaques, the occurrence of AD has been attributed to these peptides, making Aβ the most extensively validated target of therapeutics (Glenner and Wong 1984; Inyushin et al. 2019; Morris et al. 2014; Selkoe and Hardy 2016). Platelets are considered a major source of amyloid-β protein precursor (Aβ-PP), soluble Aβ (sAβ), and Aβ peptides in human circulation (approximately 90%) (Chen et al. 1995), which are analogous to those detected in the senile plaques of AD cases (Kucheryavykh et al. 2017; Scheuner et al. 1996). sAβ has been characterized in various body fluids, including CSF (Nostrand et al. 1992), plasma (Gao et al. 2018), and urine (Ghiso et al. 1997; Yun et al. 2020). Moreover, it is involved in normal platelet function (Smith 1997) and coagulation (Smith 1997; Fišar et al. 2019; Smith et al. 1990). Surprisingly, research has shown that sAβ levels do not differ between AD patients and healthy individuals. This suggests that MP-related sAβ, derived from platelets, could be produced via physiological processes (Matsubara et al. 2002). Therefore, further research is required. Endothelial Cells and AD EMPs increase in the plasma of AD patients and show elevated concentrations of E-selectin (CD62E) and PECAM (CD31], which are biomarkers for endothelial activation and apoptosis, respectively (Hunter et al. 2019a; Li et al. 2021; Williams et al. 2007). The elevated CD31/CD62E ratio detected in AD plasma specimens suggests that EMPs in AD often represent endothelial apoptosis or necrosis rather than activation. Additionally, EMPsCD31+/CD42− and EMPsCD62E+/CD42− are associated with mini-mental state examination scores along with AD cognition tests (Yun et al. 2016; Çebi et al. 2020). These exams are used to measure cognitive dysfunction in AD. Elevated EMPs are linked to an accelerated decline in cognition. Considering the role of specific EMPs in different stages of AD (from mild to severe), they appear to serve as a process-based biomarker for AD diagnosis and may be beneficial for AD staging (Yun et al. 2016; Barbour et al. 2008; Guhathakurta et al. 2017; Xue et al. 2012). The role of MPs in neurodegenerative disorders is presented in Fig. 2. MPs involvement in interconnected CNS degeneration. Prevalent mechanisms of major neurodegenerative diseases are shown. A determining mechanism linked to neuroinflammation and neurodegeneration in CNS diseases is the accumulation of proteins following initial misfolding. CNS apoptosis has also been linked to P2X7R, a purinergic receptor for ATP, which is regarded as a master controller for inflammation and a central hub for CNS dysfunction. Probable pathways for the facilitation of dysfunctional protein aggregates by MPs are shown. (A) Affected cell: (a) Protein misfolding processes: (ai) Several protective mechanisms prevent the formation of misfolded proteins. (aii) Oligomerization of misfolded proteins may occur. (aiii) Major pathological protein aggregation may follow oligomerization. (aiv) The inhibition of mTOR accelerates autophagy, leading to the clearance of pathological protein aggregates and increased cell viability. (b) Molecular inflammatory action of pathological protein aggregates: (bi) Pathological proteins may activate inflammasomes, major complexes activated after sensing specific PAMP or DAMP signals. (bii) Inflammasome activation leads to caspase-1 induction. (biii) Caspase-1 leads to the maturation of IL-1β, a major inflammatory cytokine. These cytokines are the ejected into the extracellular space by EVs. In disease conditions, inflammatory pathways may be activated by PRGN deficiency via NF-κB pathway dysregulation, especially through the blockade of TNF interaction with its receptor. (B) Injured cell: (ai-aiii) Probable pathways for protein misfolding are shown. (aiv) P2X7R facilitates the release of MPs, speeding up the spread of misfolded oligomers. (av) Additionally, P2X7R released in soluble form, (avi) may induce inflammation in target cells. Abbreviations: ALS: Amyotrophic lateral sclerosis, ASC: Apoptosis-associated speck-like protein, IL: Interleukin, LMN: Lower motor neuron, MHC: Major histocompatibility complex, MP: Microparticle, mTORI: Mechanistic target of rapamycin inhibitor, NLRP: Nucleotide-binding oligomerization domain, P2X7: P2X purinoceptor 7, PolyQ: Polyglutamine, SOD-1: Cu/Zn superoxide dismutase-1, TEM: Tetraspanin-enriched microdomain, TNFR: Tumor necrosis factor receptor, UMN: Upper motor neuron. *Notes: Protein structural data retrieved from RCSB PDB (Berman et al. 2000). Adapted in part from “Alzheimer's Brain (Disintegrating Microtubule), Progression of Parkinson's Disease in the Substantia Nigra,” by BioRender.com [2020]. Retrieved from https://app.biorender.com/biorender-templates. BioRender templates (Sheet 2011), Lee et al. [2017] (McGeer and McGeer 2011)). Created with BioRender.com. References: (Cai et al. 2018; Eriksen and Mackenzie 2008; Giuliani et al. 2019; Li et al. 2017a; Savio et al. 2018; Shao et al. 2018) Schizophrenia MPs in Fractions of Fresh CSF in Schizophrenia CSF from patients with schizophrenia manifests detectable levels of MPs, unlike most healthy cases. Nevertheless, whether genetic vulnerability in asymptomatic patients can lead to detectable MPs in the CSF remains unclear. Researchers have recently studied MPs in CSF from dizygotic and monozygotic twins and a normal singleton control group. The first and second fractions of CSF were freshly filtered and inspected via scanning electron microscopy (SEM). Analyses showed that a positive microscopic finding significantly increased the likelihood of belonging to the proband group and the co-twin-group. The results suggest that the presence of MPs in CSF may indicate genetic or environmental susceptibility related to traits in individuals with schizophrenia, schizoaffective disorder, and bipolar disorder (Johansson et al. 2012; Schwarz and Bahn 2008). ATP-Induced Release of MPs in Schizophrenia A disturbance of energy metabolism is frequently observed in schizophrenia (Clay et al. 2011). Gene expression and protein evaluations highlight a decrease in factors and enzymes involved in ATP generation and storage (Iwamoto et al. 2005; Mill et al. 2008; Mouri et al. 2007; Pennington et al. 2008; Washizuka et al. 2009). P2X7 is an ATP-gated ion channel highly expressed in immune cells (Bhattacharya 2018; Ferrari et al. 2006; Khadra et al. 2013; Lara et al. 2020; Feuvre et al. 2002; Schindler et al. 2014). This purinergic receptor is recognized as a central hub for neurological illnesses (Andrejew et al. 2020). Using the phencyclidine (PCP)-induced schizophrenia model, research showed that both genetic deletion and pharmacological inhibition of P2X7 receptors reduce schizophrenia-like behavioral alterations (Koványi et al. 2016). Cells expressing P2X7 shed MPs from their surface via a specialized mechanism that is dependent on the activation of this receptor by ATP, leading to the hydrolysis of sphingomyelin to ceramide. Additionally, this mechanism appears to involve the activation of ROCK and p38-MAPK (Kyosseva et al. 1999). Amyotrophic Lateral Sclerosis and MPs ALS is a progressive neurodegenerative characterized by the degeneration of motoneuron cells located in the anterior spinal horns (Brenner and Weishaupt 2019). ALS is generally associated with an abnormal accumulation of proteins such as superoxide dismutase-1 (SOD-1], TAR DNA-binding protein-43 (TDP-43], and sarcoma fusion transporter (FUS), which disrupt neuronal function and eventually cause cell death (Yuan et al. 2021). Other common pathologies of ALS include mitochondrial dysfunction, glutamate excitotoxicity, oxidative stress, and neuroinflammation (Bonafede and Mariotti 2017). In a lumbar puncture performed on ALS patients, CSF analysis did not show abnormalities in terms of cell count and protein concentrations, and there were no indicators of inflammation. However, SEM and fluorescence-activated cell sorting (FACS) revealed pronounced abnormalities compared to healthy controls. Furthermore, flow cytometry evaluation of two fractions of CSF from the subject with ALS was conducted to assess the specific binding of antibodies to CD42a, CD144, and CD45, and PS to lactadherin. The subject exhibited more than 100 times higher PS-positive MPs and more than 400 times higher leukocyte-derived MPs (LMPs) compared to healthy controls. The elevated number of LMPs with normal cell counts in CSF may contribute to the ALS inflammatory mechanism via the production of immune complexes with prion-like dissemination, likely due to misfolded proteins (Zachau et al. 2012). Finally, LMPs have been found to carry misfolded SOD-1 and may serve as a valuable biomarker for ALS progression (Sproviero et al. 2019). Traumatic and Ischemic Brain Injuries Endothelin-1 (ET-1), tissue plasminogen activator (tPA), and extracellular signal-regulated kinases-mitogen-activated protein kinase (ERK-MAPK) are key regulators of cerebral hemodynamics and post-fluid percussion brain injury (FPI). Following stress, MPs secreted into the blood from various cells are pro-thrombotic and pro-inflammatory and may be lysed with polyethylene glycol telomere B (PEG-TB) (Curvello et al. 2019). An in vivo investigation found that MPs released after traumatic brain injury (TBI) prevent low-pressure cerebral vasodilation and that PEG-TB protects vascular reactions by breaking down MPs. CSF levels of tPA, ET-1, and ERK-MAPK were increased upon injury, but not in the PEG-TB group. PEG-TB-treated subjects also experienced reduced hippocampal nerve cell damage (e.g., CA1 and CA3) compared with controls. Serum MP levels were elevated after FPI, which could lead to impaired hypotensive cerebrovasodilation via overexpression of tPA, ET-1, and ERK-MAPK (Bohman et al. 2016). Microglia-Derived MPs Restricted and generalized inflammation post-TBI are major determinants of secondary CNS damage, such as neuronal death and neurological dysfunction (Lu et al. 2009). The initiation and dissemination of neuroinflammation in TBI are mediated via MDMPs (Kumar et al. 2017b). In a recent study, researchers used controlled cortical impact on mature male C57BL/6 rodents to induce TBI, isolated enriched MP from the blood after 24 h, and evaluated neuroinflammation in the TBI cortex. Circulating enriched MPs from TBI animals were found to activate microglia in vitro. LPS stimulation enhanced MP release from microglia in vitro and enriched their composition with pro-inflammatory regulators, such as IL-1β and miR-155. MPs enriched with pro-inflammatory molecules, initially secreted by microglia after TBI, may induce further microglia activation, contributing to progressive neuroinflammatory feedback in the damaged brain and triggering systemic immune reactions (Kumar et al. 2017b). Platelet-Derived MPs Elevated levels of PMPCD61+ were detected in the whole blood of patients with TBI (Jacoby et al. 2001). Experimental mouse models also demonstrated that elevated levels of PMPCD41+ contribute to a predominantly hypercoagulative state (Midura et al. 2015). Additionally, another study found that, compared with arterial samples, PMPsTF and PMPsP−selectin exhibited a transcranial gradient, with higher levels in cerebrovenous samples (Nekludov et al. 2014). Endothelial-Derived MPs Researchers found that the maximum concentration of EMPs was approximately seven times higher in TBI patients compared with healthy participants (Nekludov et al. 2014). Another group subjected primary human adult brain microvascular endothelial cells (BMVECs) to rapid mechanical damage to demonstrate how endothelial cells may break down quickly during the initial stage of TBI. EMPs were extracted from the media after 2, 6, 24, and 48 h of damage. Western blot evaluations of MPs showed a time-dependent elevation in occludin, PECAM-1, and ICAM-1 following simulated mechanical impact. Additionally, ARF6, a regulator of protein cellular trafficking, was induced post-percussion (Andrews et al. 2016; Grossmann et al. 2019). Leukocyte-Derived MPs Maximum levels of LMP were approximately 1.4 times higher in TBI patients compared to healthy participants, suggesting a potential role in TBI (Nekludov et al. 2014). However, the current lack of studies necessitates further research to elucidate the role of LMPs in TBI. Mitochondrial MPs Cardiolipin (CL) is a negatively charged phospholipid located exclusively in the mitochondrial inner membrane (Chao et al. 2019). The presence of CL in the circulation suggests mitochondrial injury and secretion by damaged cells (Miranda-Díaz et al. 2019). Recent research has reported the detection of CL-exposed brain-originated mitochondrial MPs (mtMPs) at high concentrations in the peripheral circulation of rodents that underwent fluid impact damage to the CNS. These mtMPs constitute the majority of plasma Annexin-V-binding MPs detected in the acute stage of damage. Notably, mtMPs were secreted from cultured neuronal and glial cells undergoing apoptosis. The mtMPs interact with platelets to accelerate vascular leakage by disrupting the endothelial barricade. The compromised endothelial barrier allowed the release of mtMPs into the systemic circulation, promoting coagulation in both percussion-damaged and mtMP- or CL-administered rodents. This resulted in augmented fibrin breakdown, vascular fibrin accumulation, and thrombosis (Chao et al. 2019; Zhao et al. 2016). Huntington’s Disease Clashing Bioinformatics Analyses and Lab Results Bewilder the Diagnostic Value of MPs HD is an autosomal dominant hereditary neurodegenerative condition that primarily affects motor performance. HD arises from excessive repeats of the CAG base sequence in the IT15 gene, which codes for a polyglutamine sequence (PolyQ). In non-affected individuals, the number of repeats is below 35, whereas in HD cases, it exceeds 37. In HD, the IT15 gene codes for a protein with a relative molecular weight of 350,000 Da and 3144 amino acids, known as mutant Huntingtin (mHtt). HD primarily manifests as inclusion bodies and aggregates produced by mHtt in CNS neurons (Yuan et al. 2021). RNA-seq and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis have shown that the senescence of MSC-MPs may be linked to neurodegenerative conditions. Specifically, the most robustly expressed genes in late-passage MSCs and their secreted MSC-derived MPs contribute to the regulation of aging-associated illnesses such as HD and AD (Lei et al. 2017). The potential role of MPs in the carriage of mHtt has also been confirmed in vitro (Zhang et al. 2016). Conversely, a recent study indicated that platelet EVs cannot act as biomarkers for HD because they fail to link any pathological aspects of HD with EVs (Denis et al. 2018). Together, the conflicting evidence indicates the need for further investigation. Table 3 summarizes the role of MPs in neurological illnesses. Table 3Role of MPs and affected elements in neurological CNS illnessesAffected diseaseDiagnostic criteriaAffected MPsStudy modelKey observations/actionsPossible biomarker/pathway modificationsStudy lengthSpecific disease stageReferencesMSMcDonald’s criteria↑PMPClinical studyPossibly catalyzes coagulation cascadePossibly membrane inversion↑P-selectin expression, ↑GP IIb/IIIa activation, ↑PA, ↑unstimulated and agonist-stimulated plateletsObservation length: 1 yearSP MS, RR MSMorel et al. (2017)MSMcDonald’s and Poser’s criteria↑EMP, ↑PMPClinical study/ in vitro (HUVECs)MPs act at high levels, or at lower levels synergistically with inflammatory thrombin to injure the BBB↑Endothelial permeability,possibly ↑ROS, ↓ZO-1, and ↓VE-cadherinClinical: NR, in vitro: NRRR MS, SP MS, PP MS, CISMarcos-Ramiro et al. (2014)AD, MS, and Vascular dementiaNANeutrophils MPIn vitro (BMECs line)MPs damaged the transcriptomic profile of BMECs, following internalization↓TEER, ↑permeability, and deregulates tight junction genes, ubiquitin-mediated proteolysis, and vesicular transportProbable MPs internalization pathways: protein interaction, PI3K, micropinocytosis, endocytosis (dynamin, caveolae, and clathrin)NRNRAjikumar et al. (2019)ADNINCDS-ADRDA criteriaCSF MPAPP+bClinical studyDiagnostic role of MP↓APP, ↓tauNRNR, Diagnostic valueSpitzer et al. (2019)TBINAMicroglia MPIn vivo (adult male C57BL/6]/ in vitroMediates neuroinflammationLPS-simulated MPs:↑pro-inflammatory factors, ↑IL-1β, and miR-155NR, subjects underwent 24 h TBINRKumar et al. (2017a)TBINACSF MPs (in TBI vs. PEG-TB-treated TBIa)In vivo (FPI piglets)/ in vitroCauses damage to hypotensive cerebral vasodilation and induces hippocampal neuronal cell injury↑tPA, ↑ET-1, and ↑ERK-MAPKNR, measurements at 1 h post-TBIPost-TBI treatmentBohman et al. (2016)HD, ADNALP-MSC/MSC-MPIn vitro (MSCs)Is a dynamic biomarker for MSCs senescenceExpression profile of miR-146a-5p corresponds to the senescence of the parental MSC-derived MPsNRNR, a possible marker for MSC senescenceLei et al. (2017)HDMeasurement of UHDRS, TFC, and BDS scoresPlatelet EVClinical study/ in vitro (platelets)None, mystifies the role of EVs in HDNone, no correlation with UHDRS, age of cases, TFC score, or BDS scoreClinical measurements: up to 6 months after blood samplingAll stagesDenis et al. (2018)PDUK Parkinson’s Disease Society Brain diagnostic criteria↑Erythrocyte MPClinical studyIncrease, but without promising diagnostic value–Disease severity measurements: up to 6 months after blood samplingNRLamontagne-Proulx et al. (2019)ALSRevised El Escorial criteria↑LMPClinical studyA potential biomarker for disease progressionSlowly progressive: ↑SOD-1,SOD-1: LMV categorization by CD45 + ↑PRLNRNR, possible diagnostic valueSproviero et al. (2019)AD, TBI, strokeNA↑hBMEC EMPClinical study/In vitrocVariation in the expression of adhesion molecules in several MPs between gendersTNFα-induced hBMEC:vs. control: ↑M, F, PECAM-1, ↑M, F, MCAM, ↑M, E-selectin, ↑M, F, ICAM-1, ↑M, F, integrin avb3M vs. F: ↑ICAM-1, ↑MCAM, PECAM-1, ↑E-selectin, ↑integrin avb3thrombin-induced hBMEC:vs. control: ↑M, MCAM, ↑M, ICAM-1, ↑M, PECAM-1M vs. F: ICAM-1, MCAMCulture: 4 daysADHunter et al. (2019b), Erickson et al. (Erickson and Banks 2013), Xue et al. (2012)MS, CM, and viral neuropathologiesNA↑HBEC, ↑EMPIn vitro (mice MBEC line, HBEC line)Facilitates T-cell activationTNF + IFNγ-induced HBECs: antigen-presentation markers (↑ICAM-1, ↑VCAM-1, ↑CD105, ↑MHC-I, ↑MHC-II, ↑CD40], ↑FITC-Ovalbumin uptakeTNF-induced HBECs: ↑ICAM-1, ↑VCAM-1, ↑CD105, ↑MHC-I, ICOSL)Co-culture: 5 daysNRWheway et al. 2014)aPEG-TB protected against all explained pathological effectsbThe number of CSF MPs remained unchangedcSome in vitro studies with human donors were labeled as clinical studiesAD Alzheimer’s disease, ALS amyotropic lateral sclerosis, APP amyloid precursor protein, BBB blood–brain barrier, BMEC brain microvascular endothelial cell, CIS clinically isolated syndrome, CM cerebral malaria, CSF cerebrospinal fluid, EMP endothelial-derived microparticle, EMP endothelial-derived microparticle, ERK-MAPK extracellular signal-regulated kinase pathway is one of the major signaling cassettes of the mitogen-activated protein kinase, ET-1 endothelin-1, F female, FITC fluorescein isothiocyanate, hBMEC human brain microvascular endothelial cell, HUVEC human umbilical vein endothelial cell, ICAM-1 intracellular adhesion molecule-1, ICOSL inducible costimulator ligand, IL interleukin, LMP leukocyte-derived microparticle, LPS lipopolysaccharide, M male, MCAM melanoma cell adhesion molecule, MHC major histocompatiblity complex, miR microRNA, MP microparticle, MS multiple sclerosis, NA not applicable, NINCDS-ADRDA National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association, NR not reported, PA platelet aggregate, PD Parkinson’s disease, PECAM-1 platelet endothelial cell adhesion molecule, PI3K phosphatidylinositol 3-kinase, PMP platelet-derived microparticle, PP MS primary progressive multiple sclerosis, PRL progression to last visit, ROS: reactive oxygen species, RR MS relapsing–remitting multiple sclerosis, SOD superoxide dismutase, SP MS secondary progressive multiple sclerosis, TBI traumatic brain injury, TEER transendothelial electrical resistance, TNF tumor necrosis factor, UHDRS unified Huntington’s disease rating scale, VCAM vascular cell adhesion protein, VE-cadherin vascular endothelial cadherin, ZO-1 zona occludens protein 1 Role of MPs and affected elements in neurological CNS illnesses Possibly membrane inversion ↑P-selectin expression, ↑GP IIb/IIIa activation, ↑PA, ↑unstimulated and agonist-stimulated platelets ↑Endothelial permeability, possibly ↑ROS, ↓ZO-1, and ↓VE-cadherin ↓TEER, ↑permeability, and deregulates tight junction genes, ubiquitin-mediated proteolysis, and vesicular transport Probable MPs internalization pathways: protein interaction, PI3K, micropinocytosis, endocytosis (dynamin, caveolae, and clathrin) LPS-simulated MPs: ↑pro-inflammatory factors, ↑IL-1β, and miR-155 Slowly progressive: ↑SOD-1, SOD-1: LMV categorization by CD45 + ↑PRL TNFα-induced hBMEC: vs. control: ↑M, F, PECAM-1, ↑M, F, MCAM, ↑M, E-selectin, ↑M, F, ICAM-1, ↑M, F, integrin avb3 M vs. F: ↑ICAM-1, ↑MCAM, PECAM-1, ↑E-selectin, ↑integrin avb3 thrombin-induced hBMEC: vs. control: ↑M, MCAM, ↑M, ICAM-1, ↑M, PECAM-1 M vs. F: ICAM-1, MCAM TNF + IFNγ-induced HBECs: antigen-presentation markers (↑ICAM-1, ↑VCAM-1, ↑CD105, ↑MHC-I, ↑MHC-II, ↑CD40], ↑FITC-Ovalbumin uptake TNF-induced HBECs: ↑ICAM-1, ↑VCAM-1, ↑CD105, ↑MHC-I, ICOSL) aPEG-TB protected against all explained pathological effects bThe number of CSF MPs remained unchanged cSome in vitro studies with human donors were labeled as clinical studies AD Alzheimer’s disease, ALS amyotropic lateral sclerosis, APP amyloid precursor protein, BBB blood–brain barrier, BMEC brain microvascular endothelial cell, CIS clinically isolated syndrome, CM cerebral malaria, CSF cerebrospinal fluid, EMP endothelial-derived microparticle, EMP endothelial-derived microparticle, ERK-MAPK extracellular signal-regulated kinase pathway is one of the major signaling cassettes of the mitogen-activated protein kinase, ET-1 endothelin-1, F female, FITC fluorescein isothiocyanate, hBMEC human brain microvascular endothelial cell, HUVEC human umbilical vein endothelial cell, ICAM-1 intracellular adhesion molecule-1, ICOSL inducible costimulator ligand, IL interleukin, LMP leukocyte-derived microparticle, LPS lipopolysaccharide, M male, MCAM melanoma cell adhesion molecule, MHC major histocompatiblity complex, miR microRNA, MP microparticle, MS multiple sclerosis, NA not applicable, NINCDS-ADRDA National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association, NR not reported, PA platelet aggregate, PD Parkinson’s disease, PECAM-1 platelet endothelial cell adhesion molecule, PI3K phosphatidylinositol 3-kinase, PMP platelet-derived microparticle, PP MS primary progressive multiple sclerosis, PRL progression to last visit, ROS: reactive oxygen species, RR MS relapsing–remitting multiple sclerosis, SOD superoxide dismutase, SP MS secondary progressive multiple sclerosis, TBI traumatic brain injury, TEER transendothelial electrical resistance, TNF tumor necrosis factor, UHDRS unified Huntington’s disease rating scale, VCAM vascular cell adhesion protein, VE-cadherin vascular endothelial cadherin, ZO-1 zona occludens protein 1 Hurdles in Deciphering the Role of EVs in Neurological Disorders and Treatment EVs may be modified by several factors, including physiological changes (e.g., aging), CNS disease conditions (e.g., misfolded proteins), EV engineering techniques (e.g., modifying specific glycoprotein contents of EVs), and therapeutics (Ullah et al. 2019). These natural or artificially introduced modifications influence the harm or benefits associated with EVs by altering their targeting ability or content. Additionally, EVs derived from a single cell type (e.g., microglia) may exhibit dual actions (Dudvarski Stankovic et al. 2016; Konishi and Kiyama 2018; Shen et al. 2019). These findings indicate that the advantages of EV modifications in natural and disease conditions are largely unclear, as natural or artificial tweaks could both facilitate the spread and protect against CNS disease (Table 4]. The discussed evidence, combined with limitations in isolation and visualization techniques, complicates the utilization of EVs as diagnostic and therapeutic tools. Table 4Involvement of EV modifications in disease conditions and the spread of disordered proteinsCNS diseaseDysfunctional componentTreatableDisease progression reversibleReferencesADAβ and tauNoNoRajendran et al. (2006), Saman et al. (2012), Saman et al. (2014)PDα-synucleinNoNoDanzer et al. (2012), Alvarez-Erviti et al. (2011)HDPolyQNoNoZhang et al. 2016)ALSSOD-1, TDP-43, FUS, C9orf72, and ubiquitin-2NoNoBasso et al.(2013), Grad et al. (2014), Kamelgarn et al. (2016)Spongiform encephalopathiesPrionsNoNoSaá et al. (2014), Liu et al. (2017)Table adapted, in part, from Lee et al. (Lee and Kim 2017)AD Alzheimer’s disease, ALS Amyotrophic lateral sclerosis, C9orf72 C9orf72-SMCR8 Complex Subunit, PolyQ Proteins containing glutamine repeats, TDF Testis determining factor Involvement of EV modifications in disease conditions and the spread of disordered proteins Table adapted, in part, from Lee et al. (Lee and Kim 2017) AD Alzheimer’s disease, ALS Amyotrophic lateral sclerosis, C9orf72 C9orf72-SMCR8 Complex Subunit, PolyQ Proteins containing glutamine repeats, TDF Testis determining factor Insights for Future Research Mature miRs are single-stranded sncRNAs, a class of non-coding nucleic acids containing fewer than 200 nucleotides (Garcia-Elias et al. 2017). The synthesis of miRs is a multi-step process that begins with DNA transcription and involves primordial (pri-) miRs, precursor (pre-) miRs, and mature miRs (Nguyen et al. 2020). The cell–cell exchange of protein and RNA-enclosing MPs is increasingly recognized as important in intercellular crosstalk. Additionally, pre-miR-rich MSC-derived EVs enhance cell–cell communication of miRs. A study on MSC-derived EVs showed that miRs such as hsa-let-7b and hsa-let-7 g existed in a substantial pre-miR-to-mature miR ratio, as determined by microarray analysis and quantitative reverse transcription-polymerase chain reaction (qRT-PCR). The pre-miRs developed into mature miRs by RNase III in vitro (Chen et al. 2010). The therapeutic role of MSC-derived EVs has been demonstrated in AD (Cantinieaux et al. 2013; Harris et al. 2018; Qu and Zhang 2017; Reza-Zaldivar et al. 2018), PD (Vilaça-Faria et al. 2019), cerebral infarction (Dabrowska et al. 2019), and schizophrenia (Tsivion-Visbord et al. 2020). For example, in animal and in vitro studies of cerebral infarction, EVs provided robust immunoregulatory and neuroprotective functions (Dabrowska et al. 2019). In AD, the application of MSCs or conditioned media from MSCs triggered structural and functional changes that decreased apoptosis at the lesion site, regulated the pro-inflammatory response, enhanced the groundwork for axonal extension, improved neuron formation, and aided in the recovery of neurological functions (Cantinieaux et al. 2013; Harris et al. 2018; Qu and Zhang 2017; Reza-Zaldivar et al. 2018). EV treatment typically does not cause vessel blockage, shows low immunogenicity, and supports axonal formation (Murphy et al. 2019; Ortiz 2017). Therefore, cell-free treatments relying on EVs, including both exosomes and MPs, could offer a promising outlook for CNS diseases. MSC-MP therapies are summarized in Table 5. Additionally, an exemplary workflow for the preparation of cell-free EVs as therapeutics against CNS disease and their overall neuroimmunological targets is shown in Fig. 3. Table 5Stem cell-related MPs in CNS diseaseAffected diseaseMPs/Therapeutics contentStudy modelKey observations/actionsPossible biomarker/pathway modificationsStudy lengthSpecific disease stageReferencesStrokeBE-treated MSC-MP ((Proteins, and potentially miRs or mRNAs)In vivo (male Sprague–Dawley rats, pMCAO for MSC administration)/ in vitro (MSCs)Improves NVU conditionPro-inflammatory genes: ↓PGRN and ↓TNFαAnti-inflammatory genes: ↑IL-10 and ↑TSG-6Enhances vasculogenesis and endogenous neurogenesis, regulates the inflammatory reactionIn vivo assessment: until 7 daysAcute post-strokeLee et al. (2016)Stroke/ischemic brain diseaseHypoxic ADSC MPIn vivo (lower-limb ischemia nude C57Bl/6 mice)/ in vitro (HUVEC line)Enhances proliferation, migration, and invasion in HUVECs↑MiR-210, ↓RUNX3, ↑VEGF, ↑capillary densityNR, MPs collection: every 2 days, 4 weeks after ischemia induction: capillary density measurementNRZheng et al. (2018)MShPLSC MP/exosomeIn vivo (male C57BL/6]/ in vitrohPLSC EVs from RR MS and healthy donors protect against EAEPro-inflammatory cytokines ↓IL-17, ↓IFN-γ, ↓IL-1β, ↓IL-6, ↓TNFα,Anti-inflammatory cytokine: ↑IL-10 andApoptosis-related genes: ↓STAT1, ↓p53, ↓caspase-3, and ↓BaxNR, treatment: 2 weeks after immunization, daily clinical measurements until sacrificeNRRajan et al. (2016)Ischemic brain injuryPMP affecting NSCsIn vitro (NSCs) (embryos pregnant CD1Mice were utilized)Growth factors within the PMP improve neuronalcell proliferation, survival, and differentiation↑NSC → glia,Comparable effects with PDGF, FGF, and VEGF↑Akt and ERK phosphorylationNRNR, post brain injury-treatmentHayon et al. (2012)ADSC adipose-derived stem cell, Akt protein kinase B, Bax Bcl-2-associated X protein, BE brain extract, TNF tumor necrosis factor, EAE experimental allergic encephalomyelitis, ERK extracellular signal-regulated kinase, EV extracellular vesicle, hPLSC human periodontal ligament stem cell, HUVEC human umbilical vein endothelial cell, IFN: interferon, IL interleukin, miR microRNA, MP microparticle, MSC mesenchymal stem cell, NR not reported, NSC: neural stem cell, NVU neurovascular unit, PDGF platelet-derived growth factor, FGF fibroblastic growth factor, PGRN progranulin, pMCAO permanent middle cerebral artery occlusion, RR MS relapsing–remitting multiple sclerosis, RUNX3 Runt-related transcription factor 3, STAT1 signal transducer and activator of transcription 1, TSG-6 TNFα-stimulated gene-6, VEGF vascular endothelial growth factor Stem cell-related MPs in CNS disease Pro-inflammatory genes: ↓PGRN and ↓TNFα Anti-inflammatory genes: ↑IL-10 and ↑TSG-6 Enhances vasculogenesis and endogenous neurogenesis, regulates the inflammatory reaction Pro-inflammatory cytokines ↓IL-17, ↓IFN-γ, ↓IL-1β, ↓IL-6, ↓TNFα, Anti-inflammatory cytokine: ↑IL-10 and Apoptosis-related genes: ↓STAT1, ↓p53, ↓caspase-3, and ↓Bax In vitro (NSCs) (embryos pregnant CD1 Mice were utilized) Growth factors within the PMP improve neuronal cell proliferation, survival, and differentiation ↑NSC → glia, Comparable effects with PDGF, FGF, and VEGF ↑Akt and ERK phosphorylation ADSC adipose-derived stem cell, Akt protein kinase B, Bax Bcl-2-associated X protein, BE brain extract, TNF tumor necrosis factor, EAE experimental allergic encephalomyelitis, ERK extracellular signal-regulated kinase, EV extracellular vesicle, hPLSC human periodontal ligament stem cell, HUVEC human umbilical vein endothelial cell, IFN: interferon, IL interleukin, miR microRNA, MP microparticle, MSC mesenchymal stem cell, NR not reported, NSC: neural stem cell, NVU neurovascular unit, PDGF platelet-derived growth factor, FGF fibroblastic growth factor, PGRN progranulin, pMCAO permanent middle cerebral artery occlusion, RR MS relapsing–remitting multiple sclerosis, RUNX3 Runt-related transcription factor 3, STAT1 signal transducer and activator of transcription 1, TSG-6 TNFα-stimulated gene-6, VEGF vascular endothelial growth factor Utilization of MSC-derived EVs for protection against inflammatory CNS disease. The use of MPs as therapies and their anti-neuroinflammatory role is presented. (A) Preparation of EVs therapeutics: (I) After obtaining MSCs samples from human or other subjects and (II) culture or special conditioning, EVs, in particular MPs, are separated via gradient centrifugation. Through several stages, (III) cells, (IV) dead cells, and (V) debris are removed. The supernatant then undergoes (VI) density-gradient ultracentrifugation, (VII) pellet loading, and (VIII) EV extraction. (IX) Separated EVs are then administered in pre-clinical studies and trials. (B) Inflammation suppression is a main therapeutic effect of MPs therapies: The inflammatory pathway linked to NF-κB activation is blocked. This pathway comprises (I) TLR, TCR, and TNFR, which affect NF-κB. (II and III) NF-κB amplification leads to inflammasome activation (e.g., NLRP3], (IV) leading to caspase-1 activation, and (V) elevation in functional inflammatory cytokines. Abbreviations: EV: Extracellular vesicle, IL: Interleukin, MSC: Mesenchymal stem cell, NF-κB: Nuclear factor kappa B, TCR: T-cell receptor, TLR: Toll-like receptor, TNFR: Tumor necrosis factor receptor. *Notes: Protein structural data retrieved from RCSB PDB (Berman et al. 2000). Adapted from “Extracellular Vesicle Separation by Density Gradient Ultracentrifugation, NF-kB Signaling Pathways,” by BioRender.com [2020]. Retrieved from https://app.biorender.com/biorender-templates BioRender templates (Cao et al. 2011) and Pavani et al. (2019). Created with BioRender.com (BioRender.com Cw. 2020) Many recent studies have explored MPs from a limited number of origins or subtypes. Additionally, longitudinal studies tracking MP profiles are lacking. Systems biology has been applied to EV analysis in terms of metabolomics, proteomics, lipidomics, glycomics, and genomics (Gézsi et al. 2019). The application of computational modeling in longitudinal studies that explore multiple MPs could help decipher a pattern for neurological and neuropsychiatric disease by linking clinical status and classical pathophysiological aspects with multiple MP subtypes. Markers, size, contents, and cellular origin of MPs can serve as robust features for categorizing MPs. Moreover, when MPs from a single cellular origin are altered, it may indicate various physiological or disease conditions, making them hard to utilize as diagnostics due to suboptimal specificity. Finally, identifying MPs that remain unaffected by nervous system conditions could be used to normalize MP levels across different individuals. Testing such hypotheses in future research could potentially advance the field toward practical diagnostic and therapeutic solutions based on MPs. Emerging Promise of Microparticles in CNS Treatment MPs and nanoparticles show significant potential in treating CNS disorders. These small, bioactive vesicles can cross biological barriers and deliver targeted therapies for conditions like neuroinflammation, tumors, and neurodegeneration. However, key challenges in biocompatibility, precision targeting, and sustained therapeutic effects limit their current clinical application. Current Applications and Therapeutic Potential Recent studies demonstrate that MPs can significantly enhance drug delivery across the BBB, addressing the challenge that conventional drugs often cannot penetrate this barrier. For instance, superparamagnetic iron oxide nanoparticles (SPIONs) exhibit dual diagnostic and therapeutic (theranostic) capabilities in CNS applications, allowing them to serve as MRI contrast agents that visualize BBB disruptions while also delivering drugs directly to targeted CNS areas, thereby improving diagnostic accuracy and therapeutic precision (Weinstein et al. 2010). Moreover, MPs have the potential to modulate neuroinflammatory processes, which are critical in diseases like Alzheimer’s and Parkinson’s. Engineered targeted nanoparticles can deliver anti-inflammatory drugs directly to microglial cells, helping to reduce the neurotoxic effects of prolonged inflammation and potentially slowing disease progression (Zhao et al. 2020; Zhu et al. 2021). In cancer treatment, MPs are effective in targeting and reprogramming the tumor microenvironment (TME). For example, in brain metastasis models, engineered MPs have successfully suppressed tumor-promoting cells and reprogrammed immune cells to adopt a more anti-tumor phenotype, crucial for overcoming the complex immunosuppressive environment of CNS tumors (Lu et al. 2023). Key Challenges: Biocompatibility, Targeted Delivery, and Sustained Efficacy Several barriers must be addressed for microparticle therapies to achieve widespread clinical use. MPs’ size, composition, and charge are crucial for their ability to penetrate the BBB, target-specific CNS cells, and evade immune detection. Effective BBB penetration typically requires particles to be under 10 nm to optimize bioavailability and minimize toxicity (Sarin 2010). Additionally, ensuring targeted delivery involves modifying MPs with ligands or peptides to bind selectively to specific cell types, such as neurons or microglia, which reduces off-target effects and enhances therapeutic precision (Zhao et al. 2020). Finally, sustained and controlled release of therapeutic agents is essential for long-term symptom management, with lipid-insoluble systemic therapies being explored to maintain therapeutic concentrations in the brain without frequent invasive procedures (Teleanu et al. 2019). Recent Advancing Toward Clinical Use A promising approach for treating CNS disorders involves using extracellular vesicles, particularly exosomes, as microparticles to deliver miRNAs. These biocompatible exosomes can be engineered to transport specific miRNAs that modulate disease pathways, reduce inflammation, and promote neuroprotection. For instance, miRNA-124 targets neuroinflammation in Alzheimer’s and Parkinson’s diseases, while miRNA-21 protects against neuronal apoptosis in stroke, and miRNA-146a modulates inflammation in multiple sclerosis (Bravo-Miana 2024; Fu et al. 2019; Guo et al. 2023). These nanomedicine therapies can also be combined with other treatments, such as immunotherapy, to enhance immune responses against CNS tumors like glioblastoma, or gene therapy, where MPs deliver miRNAs that correct genetic defects or boost neuroprotective factors, potentially benefiting conditions like spinal muscular atrophy and Huntington’s disease (Bravo-Miana 2024; Fu et al. 2019). Conclusion While neurological diseases impose a significant burden on aging populations, efficient biomarkers and therapeutics are currently lacking. Advanced research has indicated that MPs play a prominent role in neurological disorders and offer numerous benefits as possible biomarkers and therapies. We highlighted MPs as microscopic vesicles involved in both physiological and pathological CNS mechanisms. However, the perfect isolation of EVs still faces significant hurdles. Additionally, highly similar MPs may arise in distinct CNS diseases, or their presence may suggest genetic vulnerability to disease rather than clinical manifestations of neurological illness. Some MPs also affect the course of disease in a dual-action manner. Future research should investigate the profiling of multiple MPs of different types (e.g., origins, biomarker status, content) in relation to clinical disease status. A computational approach to MP profiling could be a next-generation method for discovering novel therapies and diagnostics. In conclusion, these challenges obscure the role of MPs as robust therapeutics and biomarkers, indicating that further research is essential to unveil their promising roles in identifying neurological disorders. Acknowledgements There was no funding for the present study. Ethics approval and consent to participate are not applicable. All illustrations were created using BioRender.com. Abbreviations Alzheimer’s disease Adipose-derived mesenchymal stem cell Adenosine diphosphate Atomic force microscopy Atomic force microscopy Aamyotrophic lateral sclerosis α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid Antigen-presenting cell Apoptotic body Apoptotic body ADP-ribosylation factor 6 ADP-ribosylation factor 6 Apical-released microparticle Adenosine triphosphate Amyloid-beta Blood–brain barrier Brain-derived extra cellular vesicle Brain-derived microparticle Basic fibroblastic growth factor Basolateral-released microparticle Brain microvascular endothelial cell Cluster differentiation Clinically isolated syndrome Cardiolipin Central nervous system Cerebrospinal fluid C-X-C chemokine receptor type 4 Cyclooxygenase-2 Dendritic cell Dynamic light scattering Dopamine receptor D Experimental autoimmune encephalomyelitis Endothelial cell Excitatory postsynaptic potential Enzyme-linked immunosorbent assay Endothelial-derived microparticle Endoplasmic reticulum Extracellular signal-regulated kinases-mitogen-activated protein kinase Extracellular signal-regulated kinase Endosomal sorting complexes required for transport Endosomal sorting complexes required for transport Endothelin-1 Extracellular vesicle Fluorescence-activated cell sorting analysis Focal adhesion kinase Vascular endothelial growth factor receptor Fluid percussion brain injury Glial fibrillary acidic protein Gingival mesenchymal stem cell Human cerebral microvascular endothelial cell Hepatocyte growth factor Hematopoietic stem cell Heat shock protein Intercellular adhesion molecules Interleukin Intraluminal vesicle In utero oxycodone In utero oxycodone C-Jun NH2-terminal kinase Intraluminal vesicle Kyoto Encyclopedia of Genes and Genomes Knockout Lymphocyte function-associated antigen-1 Leukocyte-derived microparticle Lipopolysaccharide Membrane attack complex-1 Microtubule-associated protein 2 Mitogen-activated protein kinase Major depressive disorder Microglia-derived microparticle Miniature excitatory postsynaptic current Major histocompatiblity complex MicroRNA Monocyte-derived microparticle Microparticle Magnetic resonance imaging Multiple sclerosis Mesenchymal stem cell Mitochondrial microparticle Microvesicle Multivesicular body NEDD4 family-interacting protein 1 Neural stem cell Nanoparticle tracking analysis Procaspase activating compound-1 Parkinson's disease Platelet-derived fibroblastic growth factor Platelet endothelial cell adhesion molecule-1 Polyethylene glycol telomere B Platelet-derived microparticle Post-natal oxycodone Phencyclidine Protein precursor Precursor microRNA Phosphatidylserine P-selectin glycoprotein ligand-1 Paw withdrawal latency Quantitative reverse transcription-polymerase chain reaction Ras homolog family member A Rho-associated protein kinase Relapsing-remitting multiple sclerosis Release-ready pool Soluble N-ethylmaleimide-sensitive factor attachment protein receptor Spinal nerve ligation Rabies virus glycoprotein Soluble Amyloid-β Secondary progressive Multiple Sclerosis Scanning electron microscope Small extracellular vesicle Sonic hedgehog Superoxide dismutase Small non-coding RNA SRY (sex determining region Y)-box 2 Traumatic brain injury Transmission electron microscope Transcription factor Transforming growth factor T-cell-derived microparticle Tumor necrosis factor Tissue plasminogen activator Tunable resistive pulse sensing Tumor susceptibility gene 101 Vascular endothelial growth factor Very late antigen Transendothelial electric resistance Huntington’s disease Polyglutamine sequence Mutant Huntingtin Authors’ contributions SN, DND, N EB, H.F, M.S, M.M and NE conceptualized the study, wrote the manuscript, and edited the final draft. All authors contributed to the article and approved the submitted version. All authors contributed to the article and approved the submitted version. Funding There was no funding received for the present study. Availability of data and materials No datasets were generated or analysed during the current study. Declarations Conflict of interest The authors declare no competing interests. Ethics Approval Not applicable. Consent to Participate Not applicable. Consent for Publication Not applicable. Footnotes Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement No datasets were generated or analysed during the current study.